Raymond Wadlow
机构：Inova Health System, Inova Fairfax Hospital, Virginia Cancer Institute · ORCID：0000-0003-1959-5406
发表论文 145 篇 · 总被引 7120 次 · h-index 21
代表论文
- Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein–targeting antibody-drug conjugate: Results from patients with platinum-resistant ovarian/primary peritoneal/fallopian tube cancer (PROC). (2026 · Journal of Clinical Oncology · 被引 2)
- Performance of a blood-biomarker test for early detection of pancreatic ductal adenocarcinoma (PDAC) across all stages of disease versus a mixed control population. (2026 · Journal of Clinical Oncology · 被引 1)
- S2433: Randomized phase III study of second-line chemotherapy with or without panitumumab for KRAS wild type, locally advanced, or metastatic pancreatic adenocarcinoma. (2026 · Journal of Clinical Oncology)
- Tucatinib + subcutaneous (SC) trastuzumab (Tuc + Trast SC) in patients (pts) with solid tumors with ERBB2 alterations (alts): Results from the targeted agent and profiling utilization registry (TAPUR) study. (2026 · Journal of Clinical Oncology)
- Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies (2026 · Current Oncology)
- Same-Day Multidisciplinary Clinics for Patients With Newly Diagnosed Adult Solid Tumor Cancer: A Systematic Review (2026 · JCO Oncology Practice)